Recent data highlights the significant role of AI tools in clinical practice, particularly the prominence of ChatGPT among physicians. A survey conducted in March 2026 revealed that a staggering 92% of doctors across various specialties are utilizing generative AI, including both general platforms like ChatGPT and specialized healthcare tools.
This high adoption rate is consistent across the medical field, with no specialty reporting usage below 85%. Looking ahead, 85% of physicians anticipate increasing their reliance on AI tools in the coming year. Popular tools include ChatGPT (used by 83% of respondents), Gemini (50%), OpenEvidence (36%), and Wolters Kluwer’s UpToDate (32%). Clinicians primarily use these tools for tasks such as reviewing clinical guidelines, summarizing trial data, comparing drugs, and obtaining real-time treatment guidance.
The implications for pharmaceutical companies are significant. With 80% of clinicians expressing satisfaction with AI-generated answers, and many indicating that AI influences their clinical decisions, the visibility and accuracy of drug information across AI platforms become crucial. If pharmaceutical brands fail to maintain current and reliable information, they risk being overlooked in clinician searches.
To navigate this landscape, pharma marketers should adopt a dual strategy. They must optimize their brand websites for AI discovery, ensuring that drug information is structured to meet physicians' needs, and also secure visibility across clinical AI platforms. This approach, known as Generative Engine Optimization (GEO), will enhance the likelihood that AI systems retrieve and reference their content effectively, ultimately improving engagement with healthcare professionals.